Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).

Blood - 2 Apr 2026

Kaddoura Marcella, Wiedmeier-Nutor J Erin, Gupta Vikas A, Jelinek Tomas, Ziccheddu Bachisio, Shivaram Suganti, Tang Hongwei, Owens Rebecca W, Sevcikova Tereza, Fonseca Rodrigo, Durante Michael, Diamond Benjamin, Zhao Logan, Zhu Yuan X, Shi Chang-Xin, Matulis Shannon M, Mitsiades Constantine S, Landgren Ola, Usmani Saad, Hajek Roman, Chesi Marta, Bergsagel P Leif, Braggio Esteban, Boise Lawrence H, Fonseca Rafael, Kumar Shaji, Maura Francesco, Baughn Linda B

Abstract excerpt

ABSTRACT: Multiple myeloma (MM) with t(11;14)(CCND1;IGH) remains the only subset sensitive to the BCL2 inhibitor venetoclax. However, not all patients with t(11;14)(CCND1;IGH) respond to treatment, and some progress early after initial response. To investigate this, we examined 44 whole-genome and whole-exome sequencing data samples from 34 patients with t(11;14) MM treated with venetoclax. The presence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 11

Share to Chromosomes, Human, Pair 14

Share to Cyclin D1

Share to Drug Resistance, Neoplasm

Share to Multiple Myeloma

Share to Sulfonamides

Share to Translocation, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 41481388
DOI: 10.1182/blood.2025029996
PMCID: PMC13077482

Genes

CCND1
IGH
BCL2
CDKN2C
MCL1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).PMID 41481388Read ↗

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependencySemantic proximity Read ↗

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocationSemantic proximity Read ↗

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesSemantic proximity Read ↗

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Semantic proximity Read ↗

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the BedsideSemantic proximity Read ↗

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.Semantic proximity Read ↗

Targeting Bcl-2 for the treatment of multiple myeloma.Semantic proximity Read ↗

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myelomaSemantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.